Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 7/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.38 |
| ▸ | POLB | P06746 | 6/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CTDSP1 | Q9GZU7 | 4/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL6931313 | 0.99 | HPRT1 (0.46) | HPRT1MEN1KMT2APOLBTDP1 | |
| Hydrochloric Acid SCHEMBL6935179 | 0.99 | HPRT1 (0.46) | HPRT1MEN1KMT2APOLBTDP1 | |
| Potassium Ion SCHEMBL6932912 | 0.90 | HPRT1 (0.45) | HPRT1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL7684221 | 0.82 | HPRT1 (0.45) | HPRT1KMT2ACYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL6936403 | 0.78 | HPRT1 (0.44) | HPRT1MEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL1248604 | 0.77 | HPRT1 (0.37) | HPRT1MEN1KMT2APOLBTDP1 | |
| Acetic Acid SCHEMBL6932552 | 0.77 | HPRT1 (0.43) | HPRT1MEN1KMT2ALMNA | |
| Leteprinim SCHEMBL358491 | 0.72 | HPRT1 (0.50) | HPRT1LMNA | |
| SCHEMBL8768185 | 0.72 | HPRT1 (0.54) | HPRT1KMT2APOLBTDP1ALDH1A1 | |
| Leteprinim SCHEMBL6931317 | 0.72 | HPRT1 (0.49) | HPRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1294722-B1 | METHODS OF SYNTHESIS FOR 9-SUBSTITUTED HYPOXANTHINE DERIVATIVES | MERCK EPROVA AG (CH) | 2007-08-01 | — | — | EP | claimed |
| US-20050014943-A1 | Methods of synthesis for 9-substituted hypoxanthine derivatives | NEOTHERAPEUTICS, INC. | 2005-01-20 | — | — | US | claimed |
| EP-1368350-A1 | NOVEL CRYSTAL FORMS OF 9-SUBSTITUTED HYPOXANTHINE DERIVATIVES | Neotherapeutics, Inc. (US) | 2003-12-10 | — | — | EP | claimed |
| US-6630478-B2 | Administering to patient with drug-induced peripheral neuropathy an effective quantity of a purine derivative or analogue, a tetrahydroindolone derivative or analogue, or a pyrimidine derivative or analogue | NEOTHERAPEUTICS, INC. | 2003-10-07 | — | — | US | claimed |
| EP-1294722-A2 | METHODS OF SYNTHESIS FOR 9-SUBSTITUTED HYPOXANTHINE DERIVATIVES | Neotherapeutics, Inc. (US) | 2003-03-26 | — | — | EP | claimed |
| WO-2003011863-A1 | NOVEL CRYSTAL FORMS OF 9-SUBSTITUTED HYPOXANTHINE DERIVATIVES | NEOTHERAPEUTICS, INC. (US) | 2003-02-13 | — | — | WO | claimed |
| US-20020128264-A1 | Methods for treatment of conditions affected by activity of multidrug transporters | NEOTHERAPEUTICS, INC. | 2002-09-12 | — | — | US | claimed |
| WO-2001028545-A9 | USE OF CARBON MONOXIDE DEPENDENT GUANYLYL CYCLASE MODIFIERS TO STIMULATE NEURITOGENESIS | NEOTHERAPEUTICS INC (US) | 2002-08-15 | — | — | WO | claimed |
| EP-1230242-A1 | USE OF 9-SUBSTITUTED HYPOXANTHINE DERIVATIVES TO STIMULATE REGENERATION OF NERVOUS TISSUE | Neotherapeutics, Inc. (US) | 2002-08-14 | — | — | EP | claimed |
| WO-2001036419-A9 | USE OF 9-SUBSTITUTED HYPOXANTHINE DERIVATIVES TO STIMULATE REGENERATION OF NERVOUS TISSUE | NEOTHERAPEUTICS INC (US) | 2002-08-08 | — | — | WO | claimed |
| EP-1225877-A2 | USE OF CARBON MONOXIDE DEPENDENT GUANYLYL CYCLASE MODIFIERS TO STIMULATE NEURITOGENESIS | Neotherapeutics, Inc. (US) | 2002-07-31 | — | — | EP | claimed |
| US-6407237-B1 | SALT FORMATION WITH POTASSIUM HYDROXIDE; PRECIPITATION INETHANOL; CRYSTALLIZATION | NEOTHERAPEUTICS, INC. | 2002-06-18 | — | — | US | claimed |
| WO-2002004449-A2 | METHODS FOR TREATMENT OF CONDITIONS AFFECTED BY ACTIVITY OF MULTIDRUG TRANSPORTERS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | claimed |
| US-6338963-B1 | GENE EXPRESSION OF MOLECULES IN MAMMALS | NEOTHERAPEUTICS, INC. | 2002-01-15 | — | — | US | claimed |
| WO-2002000659-A2 | METHODS OF SYNTHESIS FOR 9-SUBSTITUTED HYPOXANTHINE DERIVATIVES | NEOTHERAPEUTICS, INC. (US) | 2002-01-03 | — | — | WO | claimed |
| WO-2001036419-A1 | USE OF 9-SUBSTITUTED HYPOXANTHINE DERIVATIVES TO STIMULATE REGENERATION OF NERVOUS TISSUE | NEOTHERAPEUTICS, INC. (US) | 2001-05-25 | — | — | WO | claimed |
| WO-2001028545-A2 | USE OF CARBON MONOXIDE DEPENDENT GUANYLYL CYCLASE MODIFIERS TO STIMULATE NEURITOGENESIS | NEOTHERAPEUTICS, INC. (US) | 2001-04-26 | — | — | WO | claimed |
| EP-1790344-B1 | Methods for treatment of disease-induced peripheral neuropathy and related conditions | SPECTRUM PHARMACEUTICALS INC (US) | 2011-02-23 | — | — | EP | disclosed |
| WO-2001029039-A1 | SYNTHESIS AND METHODS OF USE OF 9-SUBSTITUTED GUANINE DERIVATIVES | NEOTHERAPEUTICS, INC. (US) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001028545-A2 | USE OF CARBON MONOXIDE DEPENDENT GUANYLYL CYCLASE MODIFIERS TO STIMULATE NEURITOGENESIS | NEOTHERAPEUTICS, INC. (US) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128264-A1 | Methods for treatment of conditions affected by activity of multidrug transporters | SLC29A1, ABCB1, NUDT1 | HPRT1 8/4885MEN1 4715/4885KMT2A 4036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.